Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB821 in Advanced Melanoma and Other Solid Tumors
NCT07027488Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AB821 in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 3 more, sponsored by Yale University. Primary endpoints: Frequency of Dose-Limiting Toxicities up to 2 years, Frequency of Serious Adverse Events up to 2 years and 5 more. Started Aug 2025; status: recruiting.
02
Drugs
AB821
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)Merkel cell carcinoma (MCC)bladder cancer
Beyond the preview
Go deeper on NCT07027488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027488.